Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-5945 for Opioid-Induced Constipation
NCT01901341Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing CB-5945 with Placebo (2 arms). Primary endpoint: Overall Spontaneous Bowel Movement (SBM) Responder Rates at 12 weeks. Started Jul 2013; status: terminated.
02
Drugs
bevenopran
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01901341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01901341.